Biosite Diagnostics' cardiac panel gets green light:
This article was originally published in Clinica
The FDA has given a 510(k) marketing clearance to Biosite Diagnostics' Triage Cardiac Panel. The panel provides rapid simultaneous quantitative measurement of three important biochemical markers for heart attacks and is used in conjunction with the Triage Meter. Prior to selling the cardiac panel, the company will be required to obtain clearance for two additional 510(k)'s, related to test quality control and calibration, and another for the Triage Meter.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.